Document is current
Any future updates will be listed below
-
Authors
Foldi, Julia https://orcid.org/0000-0002-7504-867X
Blenman, Kim R. M.
Marczyk, Michal https://orcid.org/0000-0003-2508-5736
Gunasekharan, Vignesh
Polanska, Alicja https://orcid.org/0000-0002-9544-3175
Gee, Renelle
Davis, Mya
Kahn, Adriana M. https://orcid.org/0000-0002-5306-0571
Silber, Andrea
Pusztai, Lajos https://orcid.org/0000-0001-9632-6686
-
Funding
Funding for this research was provided by:
NCI (R01CA219647)
Susan G. Komen (SAC160076)
Breast Cancer Research Foundation (AWDR11559)
AstraZeneca United States (Drug supply)
Haubold Family (Philanthropic gift)
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 1 July 2024
First Online: 13 July 2024
Declarations
:
: L.P. has received consulting fees and honoraria for advisory board participation from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Stemline-Menarini, GlaxoSmithKline, Genentech/Roche, Personalis, Daiichi, Natera, Exact Sciences and institutional research funding from Seagen, GlaxoSmithKline, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. The rest of the authors have no competing interests.
: Written informed consent was obtained from all individual participants included in the study.
: This was an investigator-initiated trial, and ethical approval was obtained from the Yale Human Investigations Committee (Yale University, HIC# 1409014537) and its Clinicaltrials.gov identifier was NCT02489448. The study was conducted in accordance with the Declaration of Helsinki and adhered to Good Clinical Practice guidelines. Informed consent was obtained from all individual participants included in the study.
